1.
Australas J Dermatol
; 65(3): e75-e76, 2024 May.
Article
in English
| MEDLINE
| ID: mdl-38439213
ABSTRACT
We present a palmoplantar pustulosis case partially resistant to systemic IL-17A inhibitor (ixekizumab) treatment, and then receiving a local injection of 0.1 mL micro-dose (1 mg) IL-23 inhibitor (guselkumab) every 4 weeks for four times. The paradoxical lesion disappeared rapidly following local injection and there was no recurrence after 8 weeks of drug withdrawal. This is the first clinical report on the treatment of palmoplantar pustulosis by local injection of micro-dose guselkumab.
Subject(s)
Antibodies, Monoclonal, Humanized , Psoriasis , Humans , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal, Humanized/administration & dosage , Psoriasis/drug therapy , Female , Male , Middle Aged , Treatment Failure , Dermatologic Agents/therapeutic use , Dermatologic Agents/administration & dosage , Dermatologic Agents/adverse effects
2.
Australas J Dermatol
; 65(3): e69-e71, 2024 May.
Article
in English
| MEDLINE
| ID: mdl-38421820
3.
Int J Dermatol
; 63(4): 547-548, 2024 Apr.
Article
in English
| MEDLINE
| ID: mdl-38228398
